NCT04028349View on ClinicalTrials.gov

ZEBOVAC (Ebola Vaccine Trial, Ad26.ZEBOV/MVA-BN-Filo)

PHASE2CompletedINTERVENTIONAL
Enrollment

800

Participants

Timeline

Start Date

August 1, 2019

Primary Completion Date

March 19, 2021

Study Completion Date

March 19, 2021

Conditions
Ebola Virus Disease
Interventions
DRUG

Ad26.ZEBOV/MVA-BN-Filo

Candidate Ebola Vaccine

Trial Locations (1)

Unknown

MRC/UVRI & LSHTM Uganda Research Unit, Entebbe

All Listed Sponsors
collaborator

Epicentre, Mbarara, Uganda

UNKNOWN

collaborator

Janssen Pharmaceutica N.V., Belgium

INDUSTRY

collaborator

Coalition for Epidemic Preparedness Innovations

OTHER

collaborator

Epicentre, Paris, France.

UNKNOWN

lead

MRC/UVRI and LSHTM Uganda Research Unit

OTHER

NCT04028349 - ZEBOVAC (Ebola Vaccine Trial, Ad26.ZEBOV/MVA-BN-Filo) | Biotech Hunter | Biotech Hunter